Bladder News and Research

RSS

Stimulating electrode array assists paralyzed man to regain voluntary movements of limbs

A team of researchers from the University of California, Los Angeles (UCLA), the California Institute of Technology (Caltech), and the University of Louisville have used a stimulating electrode array to assist a paralyzed man to stand, step on a treadmill with assistance, and, over time, to regain voluntary movements of his limbs.

21 May 2011

Breakthrough reason for cautious hope among those with spinal cord injuries

A team of scientists at the University of Louisville, UCLA and the California Institute of Technology has achieved a significant breakthrough in its initial work with a paralyzed male volunteer at Louisville's Frazier Rehab Institute - the result of 30 years of research to find potential clinical therapies for paralysis.

21 May 2011

Decade-long study demonstrates immediate, long-term benefits of holmium laser treatment for enlarged prostate

New research presented at the Annual Meeting of the American Urology Association (AUA) in Washington, DC demonstrates that holmium laser therapy is a safe and durable treatment option for Benign Prostatic Hyperplasia (BPH) - an enlargement of the prostate that affects most men as they age.

21 May 2011

Technology to determine most effective chemotherapy treatment wins first prize in UC Davis Big Bang! competition

A technology that could allow cancer specialists to better determine the most effective chemotherapy treatment for a given patient won the $10,000 in first prize money in the 11th annual Big Bang! Business Plan Competition at the University of California, Davis. The contest is run by MBA students in the Graduate School of Management.

20 May 2011

MDxHealth reduces first quarter net loss by 17%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the quarter ended March 31, 2011.

18 May 2011

Silodosin helps reduce chronic prostatitis in men

New findings show that treatment with a specific alpha blocker helps reduce symptoms and improve quality of life for men with chronic prostatitis/chronic pelvic pain syndrome.

18 May 2011

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin, during a podium presentation at the 2011 American Urological Association annual meeting in Washington, D.C.

18 May 2011

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.

18 May 2011

UW's ultrathin laser endoscope gives a Google Earth view of the bladder

Bladder cancer is the fourth-most-common cancer in men and one of the most expensive cancers to treat from diagnosis to death. After initial diagnosis and surgery, patients must return to the urologist at least yearly for a costly, time-consuming and uncomfortable bladder scan. Tumors recur in more than half of patients.

17 May 2011

Calypso System can precisely deliver radiation in post-prostatectomy patients

Calypso Medical Technologies, Inc., developer of GPS for the Body® technology used for the precise tracking of cancerous tumors during radiation therapy, is exhibiting at the American Urological Association Annual Meeting (booth 4337) and will discuss recent clinical findings suggesting that the Calypso® System can be used to more precisely deliver radiation in post-prostatectomy patients.

16 May 2011

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Trillium Therapeutics Inc., a privately-held biopharmaceutical company, announced today that it has raised $1 million from a new undisclosed investor. The funds will be used to advance its lead program, TTI-1612, into clinical trials for the treatment of interstitial cystitis, also known as bladder pain syndrome. The first trial is projected to start in the second half of this year.

12 May 2011

Simple ultrasound examination may avoid complex tests for children with urinary tract infection

For infants and young children with urinary tract infection seen in the ER, a simple ultrasound examination may avoid the need for more complex x-ray tests, reports a study in the May issue of The Pediatric Infectious Disease Journal.

10 May 2011

OncoGenex first quarter revenue decreases to $1.2 million

OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.

10 May 2011

Antares Pharma first quarter total revenues increase to $3.6 million

Antares Pharma, Inc. today reported financial and operating results for the first quarter ended March 31, 2011.

9 May 2011

Study provides information about hematuria in microscopic urinalysis and urinary tract cancer

Hematuria or blood in the urine may trigger a battery of tests for urinary tract cancer that are invasive and can unnecessarily expose patients to radiation, yet the procedures contribute little to the diagnosis, according to a study by Kaiser Permanente Southern California's Department of Research & Evaluation published in the May issue of the Journal of Urology.

7 May 2011

Eurotrans-Bio awards 1.1 million grant to MDxHealth, NovioGendix for bladder cancer program

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that together with partner NovioGendix B.V., a molecular diagnostics company spun out from Radboud University Nijmegen Medical Centre, the Netherlands, has received a USD 1.1 million grant from Eurotrans-Bio to progress its bladder cancer program.

3 May 2011

SRS Medical announces pelvic health program for women

SRS Medical today announced the formation of Restore Continence™, a women's pelvic health program based on the use of a comprehensive suite of medical devices for diagnosing and treating urinary incontinence.

3 May 2011

Porter Adventist Hospital introduces new institute for robotic surgery

Robotic surgery, once the stuff of science fiction, has for some years been recognized as an important advance in surgical technique and patient experience. Now, at Porter Adventist Hospital, a comprehensive team of surgeons and staff are helping to bring in a new era in robotic surgery.

2 May 2011

Most nurses are chronically sleep deprived

Sleep has become a hot button topic in health care, at least when it comes to physicians. The fact that doctors-in-training don't get enough of it has resulted in regulations governing duty hours in resident training programs across the nation. In 2002, the Accreditation Council of Graduate Medical Education (ACGME) reduced the number of hours that resident physicians can work to 80 hours per week.

30 Apr 2011

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene Corporation: “The results for the quarter were outstanding and they reflect the ongoing momentum that Celgene is creating as we leverage our business model and position our Company for long-term success”.

28 Apr 2011

Bladder News and Research

Stimulating electrode array assists paralyzed man to regain voluntary movements of limbs

Breakthrough reason for cautious hope among those with spinal cord injuries

Decade-long study demonstrates immediate, long-term benefits of holmium laser treatment for enlarged prostate

Technology to determine most effective chemotherapy treatment wins first prize in UC Davis Big Bang! competition

MDxHealth reduces first quarter net loss by 17%

Silodosin helps reduce chronic prostatitis in men

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

UW's ultrathin laser endoscope gives a Google Earth view of the bladder

Calypso System can precisely deliver radiation in post-prostatectomy patients

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Simple ultrasound examination may avoid complex tests for children with urinary tract infection

OncoGenex first quarter revenue decreases to $1.2 million

Antares Pharma first quarter total revenues increase to $3.6 million

Study provides information about hematuria in microscopic urinalysis and urinary tract cancer

Eurotrans-Bio awards 1.1 million grant to MDxHealth, NovioGendix for bladder cancer program

SRS Medical announces pelvic health program for women

Porter Adventist Hospital introduces new institute for robotic surgery

Most nurses are chronically sleep deprived

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News